Search bioRxiv⌕ Search

Biology subjects

Valenzuela, S. M.

Publications and source records attributed to Valenzuela, S. M..

3 recordsLinked to original sources

Designing High-Affinity Progesterone Binders: Pocket Analysis and Scaffold Selection

Molecular recognition is a central component that confers detection specificity to all biosensors. The design and use of such molecules require consideration of properties including their affinity and selectivity, plus their ease of production and engineering, for downstream commercial purposes. Progesterone (P4), is a biomarker that is extensively for various diagnostic purposes. Examples include detection of P4 as an indicator of oestrus in cattle breeding, and ovulation in human IVF programs. P4 is also thought to promote strains of breast cancer, resulting in it being an environmental pollutant of interest. The present study focusses on in-silico molecular docking trials of P4 molecules with proteins such as antibodies and receptors. We describe the geometry of novel P4-binding pockets and predict key residues that favour high affinity and selectivity for P4. The in-silico molecular docking trials were performed on various mutants of an anti-P4 antibody that had lost their P4 specificity but retained selective recognition of steroids with structures closely related to cholesterol. Reverse-docking trials permitted the identification of novel scaffolds with favourable P4 binding properties. Future reports will validate the predictions of these studies through wet lab experiments. A further opportunity for this approach is to incorporate a scaffold functionality to permit binding of the protein or receptor to other molecules or sites within a biosensor electrode. These findings, and future studies, will assist in development of enhanced biosensing platforms with custom-designed P4 binders, aiding commercialisation using in-house developed reagents to meet IP requirements and minimise scaling costs. The steroid biotechnology market, valued at over $10 billion, also benefits from novel steroid binder designs, facilitating real-time steroid biomonitoring platforms for optimising steroid bioprocesses.

bioengineering↗

Functional Characterisation of Recombinant Proteins Using Ion Channel Switch Technology: A Label-Free, Wash-Free Platform for Biotechnological Applications

We present a rapid, label-free, and highly sensitive platform for characterising recombinant protein functionality using Ion Channel Switch (ICS) technology. This method enables precise evaluation of binding specificity, oligomeric state discrimination, and real-time analyte detection, addressing key challenges in protein engineering and bioprocess quality control. Using engineered single-chain variable fragments (scFv), ICS reliably distinguishes monomeric from multimeric forms, facilitates wash-free detection of analytes ranging from small molecules to larger biomolecules, and enables quantitative biosensing within seconds in real-time and continuous format. These capabilities establish ICS as a powerful tool for streamlining recombinant protein screening, with broad applications in diagnostics, therapeutic quality control, and automated bioprocess workflows.

bioengineering↗

A COVID-19 Rapid Antigen Test Employing Upconversion Nanoparticles

The COVID-19 pandemic has underscored the critical need for rapid and accurate diagnostic tools. Current methods, including PCR and rapid antigen tests (RAT), have limitations in speed, sensitivity, and the requirement for specialized equipment and trained personnel. Nanotechnology, particularly upconversion nanoparticles (UCNPs), offer a promising alternative due to their unique optical properties. UCNPs can convert low-energy near-infrared (NIR) light into higher-energy visible light, making them ideal for use as optical probes in single molecule detection and point of care applications. This study, initiated in early 2020, explores the opportunity of using highly doped UCNPs (40%Yb3+/4%Er3+) in lateral flow assay (LFA) for the early diagnosis of COVID-19. The UCNPs-based LFA testing demonstrated a minimum detection concentration of 100 pg/mL for SARS-CoV-2 antigen and 105 CCID50/mL for inactivated virus. Clinical trials, conducted in Malaysia and Western Australia independently, showed that the technique was at least 100 times more sensitive than commercial RAT kits, with a sensitivity of 100% and specificity of 91.34%. The development process involved multidisciplinary collaborations, resulting in the Virulizer device, an automated strip reader for point-of-care testing. This work sets a reference for future development of highly sensitive and quantitative rapid antigen tests, aiming for the Limits of Detection (LoD) in the range of sub-ng/mL.

bioengineering↗